KRAS 变异状态与一线免疫检查点抑制剂治疗晚期非小细胞肺癌患者结局的相关性。
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.
机构信息
Abramson Cancer Center, Division of Hematology/Oncology, University of Pennsylvania, Philadelphia.
出版信息
JAMA Oncol. 2021 Jun 1;7(6):937-939. doi: 10.1001/jamaoncol.2021.0546.
Abstract
This cohort study examines the association of status with outcomes following immune checkpoint inhibition monotherapy vs chemoimmunotherapy.
摘要
本队列研究考察了 状态与免疫检查点抑制单药治疗与化疗免疫治疗后结局的关联。
相似文献
1
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung Cancer.KRAS 变异状态与一线免疫检查点抑制剂治疗晚期非小细胞肺癌患者结局的相关性。
JAMA Oncol. 2021 Jun 1;7(6):937-939. doi: 10.1001/jamaoncol.2021.0546.
2
A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors.一项评估 PD-L1 高 KRAS 突变型一线免疫检查点抑制剂治疗的晚期非小细胞肺癌（NSCLC）患者结局的单机构研究。
Cancer Treat Res Commun. 2021;27:100330. doi: 10.1016/j.ctarc.2021.100330. Epub 2021 Feb 6.
3
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.致癌驱动子亚型、程序性死亡受体-1 配体（PD-L1）评分和吸烟状态对驱动基因非小细胞肺癌患者 PD-1/PD-L1 抑制剂疗效的预测价值。
Cancer. 2019 Apr 1;125(7):1038-1049. doi: 10.1002/cncr.31871. Epub 2018 Dec 11.
4
Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.KRAS突变在接受免疫检查点抑制剂治疗的晚期非小细胞肺癌中的预后价值：一项荟萃分析与综述
Oncotarget. 2017 Jul 18;8(29):48248-48252. doi: 10.18632/oncotarget.17594.
5
Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance in KRAS/p53 mutant lung cancers.Th17 细胞有助于 MEK 抑制剂联合抗 PD-L1 治疗 KRAS/p53 突变型肺癌的耐药。
Nat Commun. 2021 May 10;12(1):2606. doi: 10.1038/s41467-021-22875-w.
6
Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.具有 ALK 重排突变的非小细胞肺癌患者的免疫微环境特征及其临床意义。
Front Immunol. 2022 Sep 8;13:974581. doi: 10.3389/fimmu.2022.974581. eCollection 2022.
7
Efficacy of immunotherapy in -mutant non-small-cell lung cancer with comutations.免疫疗法在伴有共突变的 - 突变型非小细胞肺癌中的疗效。
Immunotherapy. 2021 Aug;13(11):941-952. doi: 10.2217/imt-2021-0090. Epub 2021 Jun 11.
8
Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).免疫检查点抑制剂在 KRAS 突变型非小细胞肺癌（NSCLC）中的疗效。
J Thorac Oncol. 2019 Jun;14(6):1095-1101. doi: 10.1016/j.jtho.2019.01.011. Epub 2019 Feb 6.
9
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer.TP53 突变与晚期非小细胞肺癌免疫检查点抑制剂治疗应答和生存延长的相关性。
Lung Cancer. 2019 Jun;132:65-71. doi: 10.1016/j.lungcan.2019.04.005. Epub 2019 Apr 8.
10
Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of -Mutated Non-Small-Cell Lung Cancer.计算生物学模型确定 - 突变非小细胞肺癌的分子亚群中 PD-（L）1 免疫治疗敏感性。
JCO Precis Oncol. 2021 Nov;5:153-162. doi: 10.1200/PO.20.00172.
引用本文的文献
1
KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis.KRAS突变作为晚期非小细胞肺癌一线免疫检查点抑制剂单药治疗的预测生物标志物：一项系统评价和荟萃分析
Curr Oncol. 2025 Jun 19;32(6):365. doi: 10.3390/curroncol32060365.
2
[Advances in Immunotherapy of KRAS-mutated Non-small Cell Lung Cancer].[KRAS 突变型非小细胞肺癌免疫治疗的进展]
Zhongguo Fei Ai Za Zhi. 2025 May 20;28(5):343-352. doi: 10.3779/j.issn.1009-3419.2025.101.08.
3
Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.纳武利尤单抗联合化疗或伊匹木单抗治疗胃食管癌：一项随机3期试验的探索性生物标志物分析
Nat Med. 2025 May;31(5):1519-1530. doi: 10.1038/s41591-025-03575-0. Epub 2025 Mar 7.
4
Immunotherapy in Non-Small-Cell Lung Cancer: A Modified Delphi Survey Consensus on First Line Treatment, Special Populations and Rechallenge.非小细胞肺癌的免疫治疗：关于一线治疗、特殊人群和再挑战的改良德尔菲调查共识
Biomedicines. 2024 Nov 29;12(12):2742. doi: 10.3390/biomedicines12122742.
5
Analysis of the benefit of anti-PD-1 monotherapy according to NGS-diagnosed genetic alterations in patients with non-small cell lung cancer.根据二代测序（NGS）诊断的基因改变分析抗程序性死亡蛋白1（PD-1）单药治疗在非小细胞肺癌患者中的获益情况。
Explor Target Antitumor Ther. 2024 Dec 18;5(6):1435-1449. doi: 10.37349/etat.2024.00283. eCollection 2024.
6
Brief Report: Not Created Equal: Survival Differences by Mutation Subtype in NSCLC Treated With Immunotherapy.简短报告：并非生来平等：免疫疗法治疗的非小细胞肺癌中不同突变亚型的生存差异
JTO Clin Res Rep. 2024 Oct 24;6(1):100755. doi: 10.1016/j.jtocrr.2024.100755. eCollection 2025 Jan.
7
First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.KRAS 突变型非小细胞肺癌的一线治疗：现状与未来展望
Cancer Biol Ther. 2025 Dec;26(1):2441499. doi: 10.1080/15384047.2024.2441499. Epub 2024 Dec 16.
8
Case report: The outcomes of neoadjuvant immunotherapy combined with chemotherapy in pulmonary sarcomatoid carcinoma: case series and literature review.病例报告：肺肉瘤样癌新辅助免疫治疗联合化疗的疗效：病例系列研究与文献综述
Front Immunol. 2024 Nov 26;15:1467755. doi: 10.3389/fimmu.2024.1467755. eCollection 2024.
9
Landscape of targeted therapies for lung squamous cell carcinoma.肺鳞状细胞癌的靶向治疗概况
Front Oncol. 2024 Oct 31;14:1467898. doi: 10.3389/fonc.2024.1467898. eCollection 2024.
10
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms.RAS 信号通路在肿瘤发生、癌症治疗和耐药机制中的作用。
J Hematol Oncol. 2024 Nov 9;17(1):108. doi: 10.1186/s13045-024-01631-9.
Zotero 插件